Ending the HIV Epidemic in New York City: From Blueprint to Implementation

Overview

No CME Credit Available
Level: Advanced
Release Date: September 28, 2016
Date of Last Review/Update: September 05, 2017
Expiration Date: September 05, 2018

This Cases on the Web (COW) activity introduces a case and presents various clinical decision points, each focusing on an HIV-infected man with possible sexually transmitted disease coinfection.

At each decision point, participants should select the option that they think is most sound and then read the presenters’ explanation of that option. Selecting the correct option links the participant to an extended discussion of the related medical findings, research-based evidence, and case management considerations.

To advance from one clinical decision point to the next, participants should click on the NEXT button located at the bottom of the page that discusses the best clinical option.

After reviewing the cases, participants may access the activity posttest and the course evaluation, both of which must be completed and submitted to claim continuing medical education (CME) credit or a certificate of participation or continuing education units (CEUs) or pharmacy credits. Please see the posttest form and course evaluation form for further instructions.

Learning Objectives

On completion of this activity, participants will be able to:

• Describe the core tenets of the New York City and New York State plan to end the HIV epidemic by 2020
• Describe data that support the use of preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) as a patient- and population-based HIV prevention strategy
• Describe the use of immediate antiretroviral therapy as an emerging strategy to treat individuals who are diagnosed with HIV infection

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians on the evolving challenges of managing HIV disease. This activity examines the vision and strategies of New York State and City to achieve the goal of ending the HIV epidemic in New York City and New York State by 2020.

Intended Audience

This enduring material is designed for physicians who are actively treating or will be treating patients with HIV infection. This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.

CME Information

Accreditation

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The IAS–USA designates this enduring material for a maximum of 1.50AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is offered from September 05, 2017 to September 05, 2018. Physicians (MDs, DOs, and international equivalents) who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Other health care practitioners will receive a Certificate of Participation.

Nursing Continuing Education Contact Hours

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.50 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

Pharmacy Continuing Education Contact Hours

Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.50 hours (0.150 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

UAN # 0761-9999-16-261-H01-P

Faculty

Author

Demetre C. Daskalakis, MD, MPH
Dr Daskalakis is Assistant Commissioner of the Bureau of HIV/AIDS Prevention and Control in the New York City Department of Health and Mental Hygiene, and Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York, New York. He served on the New York State Ending the Epidemic Task Force that drafted the New York State Blueprint to End the AIDS Epidemic.

Editor

Raphael J. Landovitz, MD
Dr Landovitz is Associate Professor of Medicine and Associate Director of the Center for Clinical AIDS Research and Education at the David Geffen School of Medicine at the University of California Los Angeles in Los Angeles, California.

Acknowledgement

Dr Daskalakis would like to thank Stacey S. Wilking, MPH, for assistance with references and obtaining updated surveillance data.

Disclosure of Financial Interests

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

Faculty

Dr Daskalakis has no relevant financial affiliations to disclose. (Updated 09/05/17)

Editor

Dr Landovitz has received research grants awarded to his institution from Gilead Sciences, Inc. He has served as a consultant to Gilead Sciences, Inc. (Updated 09/08/17)

Grant Support

2017 Grant Support

For our HIV effort:

• PLATINUM SUPPORTER
  ViiV Healthcare
• GOLD SUPPORTER
  Gilead Sciences, Inc
• SILVER SUPPORTERS
  Bristol-Myers Squibb
  Janssen Therapeutics
• BRONZE SUPPORTER
  Merck

For our viral hepatitis effort:

• GOLD SUPPORTERS
  Gilead Sciences, Inc
  Merck
• SILVER SUPPORTER
  AbbVie